Holen Sie sich die Stockscreener-App
0.5552
5.11%
-0.0299
Handel nachbörslich:
.50
-0.0552
-9.94%
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - sharewise.com
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - MSN
How Plus Therapeutics Inc. (XMP0) stock expands through international marketsQuarterly Portfolio Review & Risk Managed Trade Strategies - ulpravda.ru
HOKA Buying Guide: Can Plus Therapeutics Inc. stock continue upward trend - ulpravda.ru
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases - Sahm
Why Plus Therapeutics Inc. stock is a value investor pickStop Loss & AI Based Buy/Sell Signal Reports - ulpravda.ru
Is Plus Therapeutics Inc. stock cheap at current valuationWeekly Profit Summary & Weekly Return Optimization Plans - ulpravda.ru
Is Plus Therapeutics Inc. stock a buy in volatile markets2025 Key Lessons & Advanced Swing Trade Entry Plans - ulpravda.ru
Can Plus Therapeutics Inc. stock continue upward trendEarnings Growth Report & Daily Price Action Insights - ulpravda.ru
Plus Therapeutics completes FDA meeting on REYOBIQ trial strategy By Investing.com - Investing.com India
Plus Therapeutics stock falls after FDA meeting on REYOBIQ trial By Investing.com - Investing.com South Africa
Plus Therapeutics stock falls after FDA meeting on REYOBIQ trial - Investing.com
Plus Therapeutics Stock (PSTV) Opinions on FDA Meeting for REYOBIQ™ Approval - Quiver Quantitative
PSTV: Today's Analyst Ratings Maintains 'Buy' with Consistent Pr - GuruFocus
Plus Therapeutics (PSTV) Advances with FDA on REYOBIQ Trial for Leptomeningeal Metastases - GuruFocus
Plus Therapeutics announces read out of Type B meeting with the FDA - MarketScreener
Plus Therapeutics completes FDA meeting on REYOBIQ trial strategy - Investing.com
Plus Therapeutics, Inc. Completes FDA Type B Meeting on REYOBIQ Pivotal Trial Strategy for Leptomeningeal Metastases - Quiver Quantitative
No approved drugs for this cancer: FDA shapes path for a possible new option - Stock Titan
How Plus Therapeutics Inc. stock reacts to job market dataSector Performance Drivers & Minimal Capital Trading - ulpravda.ru
2026 world cup points table rankings: How Plus Therapeutics Inc. stock responds to policy changes2026 world cup usa national team round of 32 star players set piece tactics knockout prediction tactical review - ulpravda.ru
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analyst Downgrade: How Plus Therapeutics Inc XMP0 stock expands through international marketsMarket Risk Summary & Accurate Intraday Trade Tips - moha.gov.vn
Guidance Update: Can Plus Therapeutics Inc XMP0 stock attract analyst upgradesJuly 2025 Setups & Safe Entry Momentum Tips - moha.gov.vn
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How Plus Therapeutics Inc. stock responds to policy changes2025 Market Overview & Safe Entry Momentum Tips - ulpravda.ru
Is Plus Therapeutics Inc. (XMP0) stock a top hedge fund pick2025 Momentum Check & Real-Time Stock Price Movement Reports - Улправда
Can Plus Therapeutics Inc. (XMP0) stock ride next bull market cycleQuarterly Trade Summary & Weekly Breakout Stock Alerts - Улправда
Plus Therapeutics, Inc. (PSTV) Presents at 2025 San Antonio Breast Cancer Symposium (SABCS)Slideshow - Seeking Alpha
Plus Therapeutics (NASDAQ:PSTV) Earns "Buy" Rating from D. Boral Capital - MarketBeat
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Analyst Jason Kolbert Maintains 'Buy' Rating for Plus Therapeuti - GuruFocus
CNSide Diagnostics expands lab licenses to three more states - Investing.com
Plus Therapeutics Expands CNSide Assay Platform to State of California - The Manila Times
Plus Therapeutics adds key personnel to CNSide Diagnostics team By Investing.com - Investing.com Canada
Plus Therapeutics (PSTV) Expands CNSide Diagnostics Team with Ke - GuruFocus
Plus Therapeutics adds key personnel to CNSide Diagnostics team - Investing.com
Plus Therapeutics Announces Key Hires to Strengthen Operations at CNSide Diagnostics, LLC - Quiver Quantitative
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants - The Manila Times
Why global investors buy Plus Therapeutics Inc. (XMP0) stockWeekly Investment Recap & Reliable Breakout Forecasts - Newser
Hines Adds 3 Life-Science Tenants at Levit Green - Realty News Report
Hines' Levit Green signs 3 biotech tenants for 30K-SF of lab and office space - The Business Journals
Plus Therapeutics Reports Positive Phase 1 Data for REYOBIQ in Leptomeningeal Metastases and Glioblastoma at WFNOS/SNO Annual Meeting | PSTV Stock News - Quiver Quantitative
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - The Manila Times
Will Plus Therapeutics Inc. (XMP0) stock rise with strong economyTrade Ideas & Precise Buy Zone Tips - Newser
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):